Fosun Pharma (600196.SH): Phase III Clinical Trial of Fumining for Pediatric Low-Grade Glioma Launched - 7x24

7 x 24 Track global technological trends

Hot Topic

Day

News Topic

Fosun Pharma (600196.SH): Phase III Clinical Trial of Fumining for Pediatric Low-Grade Glioma Launched

3 week ago / Read about 0 minute

Author：小编

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a holding subsidiary of Fosun Pharma, has commenced a Phase III clinical trial in China for Fumining (Luvatinib Tablets), an innovative drug independently developed by the group, aimed at treating pediatric low-grade glioma.

Previous page：Tencent Invests HK$500 Million to Repurchase 1.005...

Next page：BNP Paribas Finalizes Acquisition of AXA Investmen...

Return to List

Hot Reading

2 day ago

Anthropic cuts off OpenAI’s access to its Claude models

2 day ago

CEOs Are Publicly Boasting About Reducing Their Workforces With AI

2 day ago

Everyone Should Have Exactly 3 Pairs of Headphones, and These Are My Picks. Here's Why

2 day ago

Rebadged Alder Lake CPU is priced higher than the new Arrow Lake chip in retailer listing